López MRE

Idioma: Español
Referencias bibliográficas: 16
Paginas: 745-752
Archivo PDF: 258.84 Kb.

RESUMEN

Pacientes que toman warfarina tienen un riesgo aumentado de sangrado, este riesgo incrementa con la interacción medicamentosa. El autor resume la información disponible acerca de combinaciones entre productos, sus efectos y guías para el manejo y vigilancia de estos casos para la atención primaria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Basters, Susan M.; Katzung, Bertram G, Trevor, Arthur J; Katzung & Trevor’s Pharmacology, 10ma Edición, McGraw-Hill Professional, Sección VI, Capítulo 34, Inciso E.

2. Blumenthal, Keith; Brunton, Laurence; Buxton Lain; Goodman & Gilman’s Manual of Pharmacology and Therapeutics, 11va Edición, McGraw-Hill Professional, 2008, Sección XI, Capítulo 54, pág. 955 a 959.

3. Chantsila, Eduard ; YH Lip, Gregory; Handbook of Oral Anticoagulation, 2da Edición, Springer Healthcare, 2013, Capítulo 7, Capítulo 3 - págs. 33 a 37, Capítulo 4 - págs. 43 a 44.

4. Colebrook, Anne; Schulman, Sam; et al., Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based Management of Anticoagulant Therapy guidelines, CHEST 2012, 141;2.

5. Crowther M., Gallus AS, Hylek EM, Palareti G., Wittkowsky A.; Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence based clinical practice guidelines. CHEST 2012; 141 (2) (suppl) :e44S-e88S.

6. Dolor, Rowena; Jacobson, Alan, Matchar, David B.; et al., Effect of Home Testing of International Normalized Ratio on Clinical Events, N Eng J Med 2010, 363;17.

7. Eldridge, Noel; Meterskey, Mark L.; Wang Yun; et al., National Trends in Patient Safety For Four Common Conditions, 2005–2011, N Eng J Med 2014, 370;4.

8. French Benjamin; Kasner, Scott E.; Kimmel, Stephen E.; et al., A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing, N Eng J Med 2013, 369;24.

9. Garg, Daniel S.; Lovegrove Maribeth C.; et al. Emergency Hospitalizations for Adverse Drug Events in Older Americans, N Eng J Med 2011, 365;21.

10. International Warfarin Pharmacogenetics Consortium, Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data, N Eng J Med 2009, 370;753.

11. Kamath, Patrick; Robert D. McBane, Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures, N Eng J Med 2013, 368;22.

12. Mahaffey, Kenneth; Manesh R.Patel; et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, N Eng J Med 2011, 365;10.

13. Murray, J.V. Murray; et al., Apixaban versus Warfarin in Patients with Atrial Fibrillation, N Eng J Med 2011, 365;11.

14. Ruff, Chirstian T.; et al., Edoxaban versus Warfarin in Patients with Atrial Fibrillation, N Eng J Med 2013, 369;22.

15. Schellong, Sebastian; Schulman, Sam; et al., Extended Use of Dabigatran, Warfarin,or Placebo in Venous Thromboembolism, N Eng J Med 2013, 368;8.

16. Schwarz, Ute I.; Yuki, Bradford; et al., Genetic Determinants of Response to Warfarin during Initial Anticoagulation, N Eng J Med 2008, 358;10.